文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

氟喹诺酮类药物与主动脉瘤或主动脉夹层风险的关联

Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection.
PubMed 文献 · JAMA Intern Med · 2020-01-01
一句话结论全国性队列研究显示,肺炎患者使用氟喹诺酮后60天内主动脉瘤/夹层相对风险升高(HR 2.57),但尿路感染队列无此关联,且绝对风险均低于0.1%,可能为残余混杂或监测偏倚。

该观察性队列研究利用美国商业理赔数据库,纳入年龄≥50岁、诊断肺炎或尿路感染后3天内启动抗生素的患者,构建两个1:1倾向评分匹配队列,控制85个基线混杂因素,比较氟喹诺酮与阿奇霉素(肺炎队列)或复方磺胺甲噁唑(尿路感染队列)使用者60天内因主动脉瘤/夹层住院的风险。结果显示肺炎队列中氟喹诺酮组风险高于阿奇霉素组(HR 2.57;95%CI 1.36-4.86),尿路感染队列中与复方磺胺甲噁唑无显著差异(HR 0.99;95%CI 0.62-1.57)。以阿莫西林为对照的次要分析结果与既往研究一致(HR 1.54;95%CI 1.33-1.79),但要求基线主动脉影像后风险升高减弱(HR 1.13;95%CI 0.96-1.33)。两个队列绝对发生率均低于0.1%,作者认为肺炎队列的相对风险升高可能源于残余混杂或监测偏倚。

要点

  • 肺炎队列中,氟喹诺酮组60天内主动脉瘤/夹层住院率0.03%,阿奇霉素组0.01%,HR 2.57(95%CI 1.36-4.86)。
  • 尿路感染队列中,氟喹诺酮组与复方磺胺甲噁唑组发生率均<0.01%,HR 0.99(95%CI 0.62-1.57),无显著差异。
  • 以阿莫西林为对照的次要分析中,氟喹诺酮组风险升高(HR 1.54;95%CI 1.33-1.79),两组发生率均<0.01%。
  • 要求基线主动脉影像后,阿莫西林对照队列风险升高减弱至无统计学显著(HR 1.13;95%CI 0.96-1.33),氟喹诺酮组发生率0.06% vs 阿莫西林组0.05%。
  • 两个队列中主动脉瘤/夹层的绝对发生率均低于0.1%。

适用人群与场景

  • 年龄50岁及以上、诊断肺炎且在启动抗生素治疗前3天内的患者(肺炎队列)。
  • 年龄50岁及以上、诊断尿路感染且在启动抗生素治疗前3天内的患者(尿路感染队列)。

研究设计与关键结果

  • 研究类型:观察性队列研究,使用美国商业理赔数据库,数据覆盖2003年1月1日至2015年9月30日。
  • 肺炎队列倾向评分匹配后共279 554例(平均年龄63.66岁,标准差10.93;女性149 976例,53.6%),氟喹诺酮与阿奇霉素各139 772对。
  • 尿路感染队列倾向评分匹配后共948 364例(平均年龄62.06岁,标准差10.33;女性823 667例,86.9%),氟喹诺酮与复方磺胺甲噁唑各474 182对。
  • 主要终点:启动治疗后60天内因主动脉瘤/夹层住院。
  • 肺炎队列:氟喹诺酮组 vs 阿奇霉素组 HR 2.57(95%CI 1.36-4.86),发生率0.03% vs 0.01%。
  • 尿路感染队列:氟喹诺酮组 vs 复方磺胺甲噁唑组 HR 0.99(95%CI 0.62-1.57),两组发生率均<0.01%。
  • 次要分析(阿莫西林对照,3 976 162对):HR 1.54(95%CI 1.33-1.79),两组发生率均<0.01%。
  • 要求基线影像的亚组(542 649对):HR 1.13(95%CI 0.96-1.33),氟喹诺酮组发生率0.06% vs 阿莫西林组0.05%。

证据类型、等级与局限

  • 证据类型:观察性队列研究(全国性理赔数据库)。
  • 局限:既往观察性研究可能存在适应症混杂或监测偏倚;本研究肺炎队列观察到的相对风险升高可能由残余混杂或监测偏倚所致。

对床旁实践的改变

  • 作者认为,肺炎队列中氟喹诺酮相关的主动脉瘤/夹层相对风险升高可能源于残余混杂或监测偏倚,两个队列绝对发生率均低于0.1%。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Previous observational studies have suggested that fluoroquinolones are associated with aortic aneurysm or dissection, but these studies may be subject to confounding by indication or surveillance bias.

OBJECTIVE: To assess the association of fluoroquinolones with risk of aortic aneurysm or aortic dissection (AA/AD) while accounting for potential confounding by fluoroquinolone indication and bias owing to differential surveillance.

DESIGN, SETTING, AND PARTICIPANTS: In an observational cohort study using a US commercial claims database, 2 pairwise 1:1 propensity score-matched cohorts were identified: patients aged 50 years or older with a diagnosis of pneumonia 3 days or less before initiating treatment with a fluoroquinolone or azithromycin and patients aged 50 years or older with a urinary tract infection (UTI) diagnosis 3 days or less before initiating a fluoroquinolone or combined trimethoprim and sulfamethoxazole. Hazard ratios (HRs) and 95% CIs were estimated controlling for 85 baseline confounders. In a secondary analysis, patients receiving fluoroquinolones were compared with those receiving amoxicillin, both with and without considering baseline aortic imaging, to address differences in detection of AA/AD before antibiotic use. Data on patients within the database from January 1, 2003, through September 30, 2015, were analyzed. Data analysis was conducted from July 23, 2019, to July 6, 2020.

MAIN OUTCOMES AND MEASURES: Hospitalization for AA/AD occurring within 60 days following treatment initiation.

RESULTS: After propensity score matching, patient characteristics were well balanced, with 279 554 patients (mean [SD] age, 63.66 [10.93] years; 149 976 women [53.6%]) in the pneumonia cohort and 948 364 patients (mean [SD] age, 62.06 [10.33] years; 823 667 women [86.9%]) in the UTI cohort. Initiators of fluoroquinolones (n = 139 772 pairs in the pneumonia cohort and n = 474 182 pairs in the UTI cohort) had an increased rate of AA/AD compared with initiators of azithromycin (HR, 2.57; 95% CI, 1.36-4.86; incidence, 0.03% for fluoroquinolones vs 0.01% for azithromycin) but no increased rate compared with initiators of combined trimethoprim and sulfamethoxazole (HR, 0.99; 95% CI, 0.62-1.57; incidence, <0.01% in both UTI groups). Secondary analysis using amoxicillin as a comparator (n = 3 976 162 pairs) produced results consistent with those from earlier studies (HR, 1.54; 95% CI, 1.33-1.79; incidence, <0.01% in both groups). Requiring baseline imaging in this cohort (n = 542 649 pairs) to address surveillance bias attenuated the increased rate (HR, 1.13; 95% CI, 0.96-1.33; incidence, 0.06% for fluoroquinolones vs 0.05% for amoxicillin).

CONCLUSIONS AND RELEVANCE: The findings of this nationwide cohort study of adults with pneumonia or UTI suggest an increased relative rate of AA/AD associated with fluoroquinolones within the pneumonia cohort but not within the UTI cohort. In both cohorts, the absolute rate of AA/AD appeared to be low (<0.1%). The increased relative rate observed in the pneumonia cohort may be due to residual confounding or surveillance bias.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Gopalakrishnan C, Bykov K, Fischer MA, et al. Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Intern Med. 2020. PMID: 32897307. doi:10.1001/jamainternmed.2020.4199

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。